Bortezomib: 7 agencies, 2004–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused bortezomib: all 23 decisive outcomes across 7 agencies were positive or positive with restrictions.
PHARMAC (New Zealand) has been easier on bortezomib than on its own caseload: it refused 0 of 6 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
The file has been open for more than a decade: 18.6 years separate the first record, 11 Oct 2004 at SMC (Scotland), from the most recent, 22 May 2023 at PHARMAC (New Zealand).
AWMSG (Wales) changed its position: recommended on 23 Jan 2013, restricted by 31 Oct 2014.
No assessment is on file from HAS (France), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for bortezomib, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Against its own class, bortezomib is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
The programme is broad: 14 distinct indication wordings are recorded for bortezomib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 31 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess bortezomib, on 11 Oct 2004; CONITEC (Brazil) did not open a file until 28 Sep 2020 — an unusually long tail of 15.9 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 16 years in total.
6 of the 7 agencies here assessed bortezomib more than once, PHARMAC (New Zealand) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for bortezomib.
The full ledger for bortezomib reads 20 recommended, 3 deferred to NICE, 3 restricted and 2 other, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 22 May 2023 | Waldenström macroglobulinaemia | PTAC advice: Medium · decision reached | source |
| CONITEC (Brazil) | 29 Sep 2020 | Mieloma múltiplo. | incorporated into SUS | source |
| PBAC (Australia) | 2018 | Multiple myeloma | The PBAC supported a proposal from the Department to streamline the current written Author… | source |
| NICE (England) | 5 Jul 2017 | NICE TA453 | terminated appraisal | source |
| SMC (Scotland) | 13 Jan 2014 | In combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adult patients with previously untreated multiple myeloma who are… | accepted (restricted) | source |
26 further decisions for bortezomib, across 7 agencies, are not shown here. They link to 20 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 31 decisions for bortezomib from 7 agencies, 2004 to 2023. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.